Table 3. Clinical data from patients who underwent chemotherapy for acute leukemias.

No.	Age	Sex	Diagnosis	Treatment	G-CSF	PPI	Peak proHNPs (μg/ml)
28	45	F	AML	HD Cytosar		3–5	7.7
29	45	F	AML	HD Cytosar		4–6	4.5
30	57	M	ALL	Hyper-CVAD	Filgrastim 0.96 mg daily	5	33.7
31	55	F	AML	HD Cytosar		—	16.2
32	66	F	AML	Da 3+10		3–5	20.2
33	66	F	AML	Da 3+8		2–5	20.4
34	67	M	AML	Da 3+10		4	28.8
35	51	M	AML	Da 3+10		—	0.98
36	44	F	AML	FLAG-IDA	Lenograstim 0.263 mg daily	3–5	19.2
37	51	M	AML	Da 3+10		5–7	18.1
38	70	M	AML	FLAG-Nov	Filgrastim 0.30 mg daily	—	2.1
39	23	M	AML	Da 3+10	Pegfilgrastim 6 mg × 1	5–7	36.3
40	70	M	AML	FLAG	Filgrastim 0.30 mg daily	5	18.6
41	65	M	AML	Da 3+10		7	24.1

Abbreviations: ALL, acute lymphoid leukemia; AML, acute myeloid leukemia; Da 3+8, daunorubicin, cytarabine; Da 3+10, daunorubicin, cytarabine; F, female; FLAG-Ida, fludarabine, cytarabine, lenograstim, idarubicin; FLAG-Nov, fludarabine, cytarabine, filgrastim, mitoxantron; G-CSF, granulocyte colony-stimulating factor; HD Cytosar, high-dose cytarabine; HNP, human neutrophil peptides; Hyper-CVAD, cyclophosphamid, vincristin, cytarabine, doxorubicin, intrathecal methotrexate; M, male; PPI, ProHNP-PMN-Interval.